Global Search

Hide Filters

Showing 1682 results

Press release / May 15, 2016

Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations

FLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients Ultibro…
Press release / Dec 09, 2020

Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer

MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1Kisqali plus endocrine therapy had a median OS of nearly five years (58.7…
Ad hoc release / Nov 24, 2020

Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event

Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth…
Press release / Oct 27, 2024

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of…
Press release / Nov 12, 2025

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate…
Story / Dec 08, 2017

Pioneering business approach expands healthcare in Indian villages

Access to Healthcare

Healthy Family program combines health education with improved access to doctors and medicines.
Press release / Jul 24, 2015

Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones

CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for…
Press release / Sep 27, 2015

Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET

In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional…
Press release / Oct 23, 2015

Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis

Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of…
Press release / Jun 11, 2021

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria

First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal…